Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02972502 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department
A Phase 4 study, sponsored by OhioHealth.
- Terminated
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
NCT02972502 is a Phase 4 study that was terminated before completion, run by OhioHealth. The registered enrollment target is 66 participants.
The verdict
NCT02972502, a Phase 4 study, was terminated before completion, sponsored by OhioHealth.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
Study Summary
Metoclopramide (Reglan) is a common agent used for relief of headaches in the emergency department (ED).In this study the investigators seek to explore another option for treatment of headaches in the ED, one that may be more efficacious and efficient. Haloperidol (Haldol), a butyrophenone class of medication, is thought to act by affecting the dopamine 2 receptor in the brain. By exploring haloperidol as an option for treatment, the investigators hope to discover a more efficient and effective medication for the treatment of non-traumatic headaches, thereby decreasing a patient's length of stay in the department and decreasing the rate of return visits for continued discomfort from the same headache. This study could lead to the increased usage of haloperidol as a first line agent in the treatment of prolonged headaches presenting to the ED.
Interventions
- DRUG Haloperidol
- OTHER Normal Saline
- DRUG Diphenhydramine
- DRUG Metoclopramide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2014-02 |
| Est. Completion | 2017-04-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02972502
The ClinicalTrials.gov registry entry for NCT02972502 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OhioHealth, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Haloperidol is the first listed.
NCT02972502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02972502 about?
NCT02972502 is a clinical study titled "Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department". Metoclopramide (Reglan) is a common agent used for relief of headaches in the emergency department (ED).In this study the investigators seek to explore another option for treatment of headaches in the ED, one that may be more efficacious and efficient. Haloperidol (Haldol), a butyrophenone class of ...
What is the current status of trial NCT02972502?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2014-02. Estimated completion is 2017-04-24.
What interventions are being tested in trial NCT02972502?
The interventions under investigation include: Haloperidol (DRUG), Normal Saline (OTHER), Diphenhydramine (DRUG), Metoclopramide (DRUG).
Who is sponsoring clinical trial NCT02972502?
This trial is sponsored by OhioHealth, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.